Última actualización: Octubre 2, 2026
Terapia con células madre autólogas
Dossier Médico & Justificación neurobiológica[citar: 1]
Patient Baseline Evaluation & Objetivos[citar: 1]
Señor. tomás, a 63-year-old male in good overall physical condition, presents with two distinct clinical challenges requiring advanced targeted cellular intervention[citar: 1]:
Bone Marrow Edema (BME) – Hip Joint[citar: 1]
Characterized by intraosseous hyperintensity, mechanical pain, localized microvascular ischemia, and structural strain on the articular cartilage[citar: 1].
Orthostatic Tremor (OT)[citar: 1]
A rare movement disorder characterized by rapid (13–18 Hz) rhythmic muscle contractions occurring primarily upon standing, causing instability and motor fatigue[citar: 1].
Oncological History & Safety Baseline[citar: 1]
The patient’s medical history notes a radical prostatectomy performed four months prior, with confirmed complete surgical oncological remission (cancer-free status with undetectable PSA)[citar: 1].
Key Therapeutic Objectives
Edema Decompression[citar: 1]
Alleviate mechanical pain, reduce intraosseous pressure, and restore bone marrow microcirculation in the hip[citar: 1].
Cartilage Preservation[citar: 1]
Prevent secondary osteoarthritis and subchondral collapse by stimulating local extracellular matrix synthesis[citar: 1].
Circuit Modulation[citar: 1]
Attenuate central neuroinflammation and modulate cerebellar-thalamic-cortical motor loops to reduce tremor[citar: 1].
Oncological Safety[citar: 1]
Strict autologous protocol guaranteeing zero tumorigenic risk and total immunogenic compatibility[citar: 1].
Expanded Autologous MSCs vs. Allogeneic Donor Banks[citar: 1]
A critical requirement in modern executive regenerative medicine is distinguishing between simple unexpanded cell fractions (or frozen donor banks) and purity-controlled, laboratory-expanded autologous mesenchymal stem cells (MSC)[citar: 1].
- Immune Sensitization & HLA Mismatch: Repeated donor cell infusions trigger donor-specific HLA antibody production, leading to rapid cell destruction[citar: 1].
- Risk of Latent Pathogens: Donor tissue carries residual risks of slow viruses and subtle genetic variations not captured in standard screens[citar: 1].
- Senectud & Cryo-Damage: Large-batch donor storage involves repeated freeze-thaw cycles, accumulating chromosomal abnormalities[citar: 1].
- 100% Immunogenic Compatibility: Harvested from the patient’s own tissue—zero risk of immunological rejection or graft-versus-host reaction[citar: 1].
- Precision Dose Expansion: Cultured over 6 a 7 days to yield tens to hundreds of millions of young, non-senescent active MSCs[citar: 1].
- Enriched Exosome Yield: High-density collection of pure paracrine extracellular vesicles rich in anti-inflammatory microRNAs and BDNF[citar: 1].
Bone Marrow Edema & Local Regenerative Dynamics[citar: 1]
The Ischemic-Inflammatory Cascade[citar: 1]
Bone marrow edema of the hip is driven by intraosseous hypertension[citar: 1]. Microvascular ischemia leads to venous stasis, elevating pressure within the femoral head and triggering severe nociceptive pain signals[citar: 1].
Damaged stromal cells release pro-inflammatory cytokines (IL-1β, IL-6, TNF-α)[citar: 1]. This cytokine storm over-activates osteoclasts, causing localized bone resorption and micro-trabecular breakdown[citar: 1].
Local MSC Mechanisms of Action[citar: 1]
- A. M1-to-M2 Macrophage Shift: PGE2 and TGF-β convert destructive M1 immune cells into reparative M2 macrophages[citar: 1].
- B. Neo-Angiogenesis: VEGF and bFGF secretion builds new capillaries, draining fluid and normalizing bone pressure[citar: 1].
- do. Matrix Regeneration: Direct stimulation of Collagen Type II and Aggrecan synthesis to reinforce cartilage[citar: 1].
Crossing the Blood-Brain Barrier in Orthostatic Tremor[citar: 1]
Orthostatic tremor originates from central motor network synchronization involving cerebellar-thalamic-cortical loops[citar: 1]. Systemic administration of expanded autologous cells addresses central targets via dual penetration mechanisms[citar: 1]:
1. Trans-Endothelial MSC Migration[citar: 1]
Under neuro-inflammatory signaling, cerebral microvascular cells express ICAM-1/VCAM-1 adhesion molecules[citar: 1]. Intravenously infused MSCs adhere to these receptors and undergo trans-endothelial migration directly into brain parenchyma[citar: 1].
2. Nanoscale Exosomal Penetration[citar: 1]
MSCs release 30–150 nm extracellular vesicles (exosomas)[citar: 1]. Their lipid bilayer structure allows them to cross the intact Blood-Brain Barrier (BBB) freely via receptor-mediated transcytosis, delivering regulatory microRNAs (miR-124, miR-21) to central neurons[citar: 1].
Neurotrophic Support Panel[citar: 1]
Targeted paracrine delivery supplies BDNF (enhances GABAergic neuron survival)[citar: 1], NGF (promotes axonal repair and dendritic sprouting)[citar: 1], y GDNF (protects central motor networks against oxidative strain)[citar: 1].
GMP Cleanroom Verification & Product Passport[citar: 1]
Cellular expansion is conducted within integrated Good Manufacturing Practice (BPM) cleanroom suites operating under ISO Class 5 (Class A) laminar workstations and ISO Class 7/8 cleanroom ambient control[citar: 1].
| Quality Test Parameter[citar: 1] | Testing Methodology[citar: 1] | Acceptance Criteria[citar: 1] | Clinical Significance[citar: 1] |
|---|---|---|---|
| Cell Viability[citar: 1] | Automated Fluorescent Staining[citar: 1] | ≥ 95% Viable[citar: 1] | Guarantees maximal cell survival post-injection[citar: 1] |
| Cell Identity (Flow Cytometry)[citar: 1] | Surface Marker Panel[citar: 1] |
CD73+, CD90+, CD105+ (≥95%)[citar: 1] CD45-, CD34-, HLA-DR- (≤2%)[citar: 1] |
Confirms pure MSC lineage; excludes hematological cells[citar: 1] |
| Pruebas de esterilidad[citar: 1] | Automated Blood Culture System[citar: 1] | 100% Negative[citar: 1] | Absolute freedom from bacterial and fungal pathogens[citar: 1] |
| Endotoxin Content[citar: 1] | LAL (Limulus Amebocyte) Assay[citar: 1] | < 0.25 EU/mL[citar: 1] | Excludes pyrogenic bacterial by-products[citar: 1] |
| Mycoplasma Screening[citar: 1] | Real-Time PCR Assay[citar: 1] | Negative[citar: 1] | Rules out cryptic intracellular contamination[citar: 1] |
| Karyotypic Stability[citar: 1] | Cytogenetic G-Banding[citar: 1] | Normal Diploid[citar: 1] | Confirms zero acquisition of chromosomal mutations[citar: 1] |
Cellular Product Passport[citar: 1]
CERTIFICATE OF ANALYSIS & TRACEABILITY[citar: 1]
7-Day Clinical & Laboratory Schedule (Barcelona)[citar: 1]
Comprehensive consultation, orthopedic review, and mapping of hip bone marrow edema lesions[citar: 1]. Collection of 10 mL peripheral blood/tissue aspirate under sterile conditions for primary MSC isolation[citar: 1].
Incubation in automated GMP incubators (37°C, 5% CO₂) expanding cells to therapeutic yield[citar: 1]. Harvesting and purification of cellular exosomes via tangential flow filtration[citar: 1].
Real-Time PCR mycoplasma testing, endotoxin verification, flow cytometry identity validation, and issuance of official Product Passport[citar: 1].
Local Delivery: Target-guided intra-articular/subchondral administration into hip joint[citar: 1].
Systemic Delivery: High-dose IV administration of MSCs and exosomes for central BBB crossing and neuro-modulation[citar: 1].
Expected Clinical Outcomes & Follow-up Plan[citar: 1]
1 a 4 Semanas[citar: 1]
Decompression of bone marrow pressure; progressive reduction in mechanical hip pain and early systemic anti-inflammatory effect[citar: 1].
1 a 6 Meses[citar: 1]
Radiological clearing of BME on MRI[citar: 1]; structural stabilization of subchondral bone; modulation of motor networks reducing tremor intensity[citar: 1].
Long-Term Protocol[citar: 1]
Follow-up online consultation at Month 1[citar: 1]; repeat hip MRI scan at Month 3[citar: 1]; full neurological evaluation at Month 6[citar: 1].
Revisión de casos científicos
¿Le gustaría saber si los programas clínicos actuales, desarrollos recientes de investigación, o enfoques emergentes pueden ser relevante para su situación individual?
Envía tu pregunta a nuestro equipo científico. La oficina central de NBScience en el Reino Unido coordina consultas a través de la red internacional de centros médicos, científicos, y consultores especializados.
- Revisión de la información que proporcionas.
- Información relevante sobre programas clínicos y de investigación.
- Una respuesta clara y centrada en tu situación.
Sin compromiso. Su pregunta será revisada de forma confidencial..
Información educativa y de investigación únicamente.. Este servicio no constituye consejo médico, diagnóstico, prescripción, o un personalizado recomendación de tratamiento.
